Mankind Pharma Share Price Gains Over 4%; Reports Q2 FY27 Earnings Results: Total Income Up 17% YoY

On October 26, 2026, Mankind Pharma Limited reported a substantial increase in its financial performance for the quarter ending September 30, 2026, as per the exchange filings.  

The company's total income rose by 17% year-on-year to ₹4,432.71 crore, while net profit surged by 37.7% to ₹716.12 crore. 

Mankind Pharma Q2 FY27 Earnings Results 

In the September 2026 quarter, Mankind Pharma's total income increased to ₹4,432.71 crore, up from ₹3,789.03 crore in the same period last year.  

The net profit for the quarter also saw a significant rise, reaching ₹716.12 crore compared to ₹520.18 crore a year ago. This growth is attributed to disciplined execution and strategic business fundamentals. 

Half-Year Financial Overview 

For the half-year ending September 30, 2026, the company's total income was ₹8,508.30 crore, marking a 14.4% increase from the previous year's corresponding period. Net profit for this period rose by 33.7% to ₹1,290.21 crore.  

The company's operational revenue for the first half of fiscal year 2027 was ₹8,368.00 crore, reflecting a 15.1% year-on-year growth. 

Segmental Market Performance 

During the quarter, Mankind Pharma's core domestic division recorded sales of ₹3,657.00 crore, while international exports contributed ₹681.00 crore.  

The domestic business, excluding consumer healthcare, grew by 15.9% year-on-year to ₹3,428.00 crore. The consumer healthcare segment posted ₹229.00 crore in sales. 

Read More: JSW Energy Share Price in Focus; Board to Consider Fund Raise on October 28, 2026! 

Medical Specialty and Consumer Healthcare 

The company reported that secondary sales outpaced the broader Indian Pharmaceutical Market by 1.1 times. Chronic categories, particularly cardiac therapies, demonstrated mid-teen growth.  

The acute therapeutic segments, including gastrointestinal formulations, also showed strong results. The consumer healthcare vertical faced softer category consumption but achieved market share gains, with modern trade and e-commerce platforms comprising 18% of segment revenue. 

Mankind Pharma Share Price Performance 

As of October 26, 2026, at 3:30 PM, Mankind Pharma share price on NSE was closed at ₹2,312.00, up by 4.49% from the previous closing price. 

Conclusion 

Mankind Pharma's financial results for the September 2026 quarter show a 17% YoY increase in total income to ₹4,432.71 crore and a 37.7% YoY rise in net profit to ₹716.12 crore. The half-year figures also reflect a 14.4% YoY growth in total income and a 33.7% YoY increase in net profit. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.